Human embryonic stem cells can become virtually any cell type in the body, a property that makes them one of the most promising tools in regenerative medicine and one of the most ethically contested. Derived from early-stage embryos just days old, these cells sit at the intersection of groundbreaking therapy and deep moral disagreement about when human life begins. As of late 2024, more than 1,200 patients have received therapies grown from these cells across 116 clinical trials, with no widespread safety alarms so far. Yet the basic tension that ignited debate in 1998, when the first human embryonic stem cell lines were isolated, has never fully resolved.
Where These Cells Come From
Human embryonic stem cells (hESCs) are harvested from a structure called the inner cell mass of a blastocyst, the hollow ball of cells that forms roughly five days after fertilization.1PubMed. Derivation of human embryonic stem cell lines after blastocyst microsurgery The blastocysts used are typically surplus embryos created during in vitro fertilization (IVF) that would otherwise be discarded or frozen indefinitely. The standard approach involves chemically or mechanically stripping away the outer shell of the embryo, then isolating the inner cell mass through a technique called immunosurgery.2Cell Stem Cell. Optimal Timing of Inner Cell Mass Isolation Increases the Efficiency of Human Embryonic Stem Cell Derivation and Allows Generation of Sibling Cell Lines This process destroys the embryo, which is the root of the ethical controversy.3PubMed Central. Isolation, Culture, and Functional Characterization of Human Embryonic Stem Cells: Current Trends and Challenges
The first successful isolation of hESC lines was reported in 1998 by James Thomson’s group at the University of Wisconsin. Those original lines could proliferate for months while retaining the ability to form tissues from all three primary layers of the developing body: gut-like tissue, bone and muscle, and neural tissue.4PubMed. Embryonic stem cell lines derived from human blastocysts This property, called pluripotency, is maintained by a small network of master genes, particularly OCT4, SOX2, and NANOG, which reinforce each other in looping circuits that keep the cell in its undifferentiated state.5Cell. Multivalent Control of Human Embryonic Stem Cell Pluripotency by OCT4, SOX2, and NANOG Understanding these circuits has been essential not only for maintaining hESCs in culture but also for the later invention of methods to reprogram ordinary adult cells back into a stem-cell-like state.
Growing Cells Without Animal Contamination
Early hESC culture relied on layers of inactivated mouse cells and fetal bovine serum to keep the stem cells alive and dividing. That worked in the lab but posed a serious problem for clinical use: any cells destined for transplant into a patient could carry animal viruses or trigger immune reactions from residual animal proteins.6PubMed Central. Human embryonic stem cell cultivation: historical perspective and evolution of xeno-free culture systems Over the past two decades, researchers have developed fully defined, animal-free culture systems. One example is a medium that supported the derivation of new hESC lines and kept them growing for more than 80 passages (essentially, more than 80 rounds of splitting and regrowing the cells) using only recombinant human proteins and synthetic ingredients.7PLoS ONE. A Defined and Xeno-Free Culture Method Enabling the Establishment of Clinical-Grade Human Embryonic, Induced Pluripotent and Adipose Stem Cells These xeno-free protocols are now standard for any hESC product headed toward clinical trials, because regulators require a clean chain of custody from embryo to patient.
Therapeutic Applications in Development
The most advanced clinical programs for hESC-derived therapies cluster around a few organ systems where the body’s own repair machinery falls short. Here is where things stand in the most active areas.
Eye Disease
The retina was one of the first targets because the eye is small, surgically accessible, and partially immune-privileged. Researchers showed in animal models that hESC-derived retinal pigment epithelium (RPE) cells could survive for more than 220 days after transplantation and preserve vision in a dose-dependent way, with no tumor formation.8PubMed. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration An early human trial transplanted these cells into one patient with Stargardt’s macular dystrophy and one with dry age-related macular degeneration. After four months, there were no signs of uncontrolled growth or immune rejection, and both patients showed some visual improvement.9The Lancet. Embryonic stem cell trials for macular degeneration: a preliminary report
A larger follow-up study with 12 participants tempered the optimism, however. While subretinal pigmentation consistent with cell survival appeared in every patient, careful vision testing showed no clear benefit at 12 months. At the highest dose, localized retinal thinning and reduced sensitivity raised the possibility of harm.10PubMed Central. Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration The cells seem to survive the transplant, but making them actually restore function in a diseased retina remains an unsolved challenge.
Parkinson’s Disease
Parkinson’s results from the death of a specific population of dopamine-producing neurons in the midbrain. Researchers have been coaxing hESCs into this exact cell type for two decades. Early protocols confirmed that these lab-grown dopamine neurons fire real action potentials, release dopamine, and can reverse movement deficits when transplanted into rats with experimentally induced Parkinson’s.11PubMed Central. Derivation of midbrain dopamine neurons from human embryonic stem cells12PubMed Central. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells
A phase 1/2 human trial has now shown early evidence that grafted hESC-derived dopamine cells survive in the brains of people with Parkinson’s. Brain imaging revealed increased dopamine activity in the grafted regions, with the high-dose group seeing roughly an 11 to 15 percent increase in dopamine uptake compared with baseline.13Nature Medicine. Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial Those numbers are modest and the trial was designed primarily to test safety, but the fact that transplanted cells are functioning in the human brain at all represents a milestone that was purely hypothetical just a few years ago.
Diabetes
Type 1 diabetes destroys the insulin-producing beta cells of the pancreas. Multiple groups have shown that hESCs can be directed through a sequence of developmental stages toward the pancreatic lineage. One landmark study demonstrated that hESC-derived pancreatic cells, once implanted in mice, produced human insulin at levels comparable to transplanting roughly 3,000 actual human islets. The implanted cells also protected mice from chemically induced diabetes.14Nature Biotechnology. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo Earlier work had already shown that these cells could switch on the right genes and release C-peptide, a reliable marker for real insulin production.15PubMed. Directed differentiation of human embryonic stem cells into the pancreatic endocrine lineage Human trials for diabetes cell replacement are now under way at several companies.
Heart Repair
Heart muscle cells barely regenerate after a heart attack, so researchers have long hoped to grow replacement muscle from hESCs. Large-animal studies show it can be done. In monkeys, transplanted hESC-derived heart muscle cells formed large grafts within the scar tissue of damaged hearts. But the cells also caused non-fatal ventricular arrhythmias, an unsettling complication that did not appear as prominently in smaller animals.16PubMed Central. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts A pig study confirmed the pattern: substantial new muscle growth, but frequent bouts of abnormal heart rhythm that eventually resolved on their own within about four weeks.17PubMed Central. Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias Solving the arrhythmia problem, perhaps by using more mature cells or delivering anti-arrhythmic drugs alongside them, is the main barrier to human cardiac trials.
How Far Clinical Trials Have Come
By December 2024, 116 clinical trials with regulatory approval had tested 83 different products derived from human pluripotent stem cells, including both hESCs and induced pluripotent stem cells. The most targeted diseases are eye conditions, central nervous system disorders, and cancer. Across all of these, more than 1,200 patients have been dosed, collectively receiving an astronomical number of cells, with no generalizable safety concerns emerging so far.18PubMed. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update That safety track record is encouraging but still young; most follow-up periods are measured in months to a few years, and the full picture of long-term risks will take longer to develop.
Safety Risks That Have Not Disappeared
Two biological hazards shadow every hESC therapy: tumor formation and immune rejection.
Because hESCs are defined by their ability to become any cell type, undifferentiated cells left in a transplant can form teratomas, disorganized growths containing jumbled mixtures of tissue. Animal experiments have shown a tight relationship between the number of undifferentiated cells injected and how quickly a teratoma appears. Even as few as a couple hundred cells can eventually seed a tumor, though it takes months rather than weeks.19Stem Cell Research. Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies The clinical workaround is to differentiate the cells as thoroughly as possible before transplantation and to use assays that screen for any residual undifferentiated cells. So far, no teratomas have been reported in human trials, but ensuring the purity of billions of cells at manufacturing scale remains a significant quality-control challenge.
Immune rejection is the other persistent problem. hESC-derived tissues carry a donor immune profile that may not match the recipient, so the patient’s immune system can attack the graft just as it would a mismatched organ transplant.20PubMed. Immunogenicity of human embryonic stem cells One strategy is to build banks of hESC lines with diverse immune profiles so that a close match can be found for most patients.21PubMed Central. Immunological considerations for embryonic and induced pluripotent stem cell banking A newer and potentially more powerful approach uses gene editing to delete or modify the immune markers on hESC lines, creating “universal” donor cells that should be tolerated by almost any recipient without lifelong immunosuppressive drugs.22PubMed. Establishment of universal human embryonic stem cell lines Both approaches are still being validated in clinical settings.
The Embryo Destruction Problem
The central ethical objection to hESC research has always been straightforward: isolating the inner cell mass destroys a human embryo. For people and traditions that assign full moral status from the moment of fertilization, this amounts to taking a human life in exchange for research material. For others, a five-day-old blastocyst of roughly 200 cells lacks the features typically associated with personhood, such as a nervous system, sentience, or individuality (since it can still split into twins). These positions have been debated extensively since 1998 without converging, and there is no scientific experiment that can resolve what is fundamentally a moral question about the value of potential human life.
A middle-ground framework used by many research ethics bodies treats the early embryo as deserving of special respect but not the same protections as a born person. Under this view, research on surplus IVF embryos that would otherwise be discarded can be justified if it has the potential to relieve serious suffering. The tricky part is that technologies keep shifting the goalposts. Researchers can now create embryo-like structures from stem cells in the lab, blurring the line between an embryo and a laboratory construct. Determining what moral status these “blastoids” and synthetic embryo models deserve requires more fine-grained thinking about what gives a biological entity moral standing.23PubMed Central. The moral status of human embryo-like structures: potentiality matters?
Consent and the Donor’s Role
A less publicized ethical concern involves the women whose eggs and embryos supply hESC research. Most hESC lines come from embryos donated by IVF patients, but the consent process has gaps. A survey of 66 egg donor consent forms from US fertility clinics found that only 30 percent informed donors that embryos created from their eggs could end up in research.24PubMed Central. Informing egg donors of the potential for embryonic research: A survey of consent forms from US IVF clinics Even among clinics that actively allowed embryo donation for stem cell research, just 8 percent told egg donors about that possibility. In Canada, where regulation is more centralized, fertility clinics play the primary role in the consent process and researchers typically have no direct contact with donors at all.25PubMed. An investigation of embryo donation, informed consent, and research oversight in Canadian human embryonic stem cell research
Payment adds another layer. When women are asked about providing eggs specifically for stem cell research rather than for another patient’s fertility treatment, only about 2 percent would do so without compensation. Roughly a third said they would participate for less than the going rate paid to commercial egg donors, while another third wanted the full market rate.26PubMed Central. Payment of egg donors in stem cell research in the USA This raises the uncomfortable question of whether financial incentives could exploit economically vulnerable women, particularly given that egg retrieval involves hormonal stimulation and a surgical procedure with real, if generally manageable, risks.
A Patchwork of National Regulations
There is no global consensus on how to regulate hESC research. Within the European Union alone, national laws range from permissive (the UK allows the creation of embryos specifically for research, under license) to prohibitive (Germany and Italy restrict it sharply). These differences reflect divergent cultural, ethical, and religious views on the status of the embryo.27PubMed. The changing landscape of European and international regulation on embryonic stem cell research In the United States, federal funding has oscillated with presidential administrations: restricted under George W. Bush, expanded under Obama, and subject to ongoing legal challenges since. Private funding has always been unrestricted, which means that the practical effect of federal policy is mainly to determine which labs can compete for government grants, not whether the research happens at all.
Stem cell banks have emerged as one way to standardize the field across borders. By storing well-characterized, quality-controlled hESC lines, these banks can supply researchers worldwide with the same starting material. The complication is that different national banks operate under different policy, regulatory, and commercial frameworks, making it genuinely difficult to share cell lines and data across borders.28PubMed Central. From banking to international governance: fostering innovation in stem cell research A researcher in Singapore might receive a cell line derived under British law but need to comply with local rules that were never written with that specific scenario in mind.
Alternatives That Sidestep Some Ethical Issues
The development of induced pluripotent stem cells (iPSCs) in 2006 offered a way to get embryonic-like cells without using embryos at all. By introducing a handful of genes into ordinary skin or blood cells, researchers can wind the clock back and produce cells that behave much like hESCs. iPSCs have their own limitations, though. Most lines maintain a normal set of chromosomes, but some pick up abnormalities during reprogramming, including a recurring problem with an extra copy of chromosome 12 that accounts for a large fraction of the chromosomal errors seen. Each iPSC line also carries roughly ten new mutations in protein-coding regions, plus hundreds to thousands across the broader genome.29Oxford Academic (Stem Cells). Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine Whether those mutations matter clinically depends on where they land and how the cells are used, but the concern is enough that hESCs remain the gold standard benchmark against which iPSCs are compared.
Another approach is somatic cell nuclear transfer (SCNT), sometimes called therapeutic cloning. This involves placing the nucleus of a patient’s own cell into a donor egg that has had its nucleus removed, then coaxing it to develop into a blastocyst from which stem cells can be derived. In 2013, researchers achieved this in humans for the first time, producing patient-matched stem cell lines.30PubMed Central. Human embryonic stem cells derived by somatic cell nuclear transfer SCNT avoids the immune-rejection problem, since the resulting cells carry the patient’s own DNA. But it still requires human eggs and still creates and destroys embryos, so it sidesteps some ethical objections while raising others.
More recently, researchers have begun assembling embryo-like structures, called blastoids, entirely from stem cells in the lab. These can mimic early development closely enough to be scientifically useful for studying implantation and early pregnancy failure. But the closer blastoids get to resembling real embryos, the more they raise the same moral questions that hESC research does. Bioethicists have argued that existing regulations, many of which were written with IVF embryos in mind, are not well suited to handle entities that were never fertilized and may never be able to develop into a person but look and behave like early embryos under a microscope.31PubMed Central. The regulation of human blastoid research: A bioethical discussion of the limits of regulation
Why hESCs Have Not Been Replaced
Given that iPSCs exist and carry fewer ethical objections, it is reasonable to ask why researchers do not simply abandon hESCs. The answer is partly scientific and partly practical. hESCs have a quarter-century track record of characterization. Their behavior in culture is well understood, their gene-expression profiles are deeply catalogued, and they serve as the reference point against which every alternative cell source is measured. When a new iPSC-based therapy enters testing, regulators and scientists inevitably compare its safety and potency data to what has already been established with hESCs. Abandoning the reference standard would make it harder, not easier, to evaluate whether alternatives are good enough.
There are also biological differences that have not been fully explained. hESCs and iPSCs are broadly similar, but iPSCs sometimes carry an “epigenetic memory” of the tissue they came from, meaning a skin-derived iPSC line may have a subtle bias toward becoming skin cells again. For some therapeutic applications that may not matter, but for others, especially those that require very precise control over differentiation, hESCs remain the more predictable starting material. The field is moving toward a future where multiple cell sources coexist, each chosen for the context where it performs best, rather than a clean replacement of one technology by another.
Lab-Grown Embryo Models and the Next Ethical Frontier
The ethical landscape is shifting in ways that few people anticipated when the hESC debate began. The ability to create synthetic embryo-like structures from stem cells means that the question “does this research destroy a human embryo?” no longer has a clean yes-or-no answer. A blastoid made from iPSCs was never a fertilized egg, yet it can form structures that resemble a real blastocyst closely enough to be useful for studying the earliest stages of human development. Some models can even begin the process of gastrulation, the stage where the body’s basic plan starts to take shape.23PubMed Central. The moral status of human embryo-like structures: potentiality matters?
Many countries enforce a “14-day rule” that prohibits culturing human embryos beyond 14 days after fertilization, a boundary chosen decades ago because it roughly corresponds to the appearance of the primitive streak and the point beyond which twinning can no longer occur. But blastoids and synthetic embryo models were not covered by that rule, because they did not exist when it was written. Whether they should fall under the same restriction, a different one, or none at all is actively debated. The International Society for Stem Cell Research has issued updated guidelines, but national laws lag behind the science in most jurisdictions. For researchers, clinicians, and the public, the conversation about what counts as an embryo, and what protections it deserves, is far from settled.